COLLEGIUM PHARMACEUTICAL, INC
COLLDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
27dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
How COLL's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oxycodone DETERx | Phase 3 | Chronic Low Back Pain | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in COLLEGIUM PHARMACEUTICAL, INC's drug pipeline?→
CatalystAlert tracks 1 drug candidate in COLLEGIUM PHARMACEUTICAL, INC's (COLL) pipeline across Phase 3. Its lead program is Oxycodone DETERx (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is COLLEGIUM PHARMACEUTICAL, INC's next FDA catalyst?→
COLLEGIUM PHARMACEUTICAL, INC's (COLL) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track COLL biotech catalysts?→
Add COLL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow COLLEGIUM PHARMACEUTICAL, INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.